Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma

Cancer

Volumn 109, Issue 12, 2007, Pages 2532-2540

  Takeuchi, Akihiko ^a,b   Yamamoto, Yasuhiko ^a   Tsuneyama, Koichi ^c   Cheng, Chunmei ^c   Yonekura, Hideto ^a,d   Watanabe, Takuo ^a   Shimizu, Katsuji ^b   Tomita, Katsuro ^a   Yamamoto, Hiroshi ^a   Tsuchiya, Hiroyuki ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chondrosarcoma; Diagnosis; Enchondroma; Endogenous secretory RAGE (esRAGE); High mobility group box 1 (HMGB1); Prognostic marker; Receptor for advanced glycation endproducts (RAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHONDROSARCOMA; CONFOCAL MICROSCOPY; ENCHONDROMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHONDROMA; CHONDROSARCOMA; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 34250186432     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22731     Document Type: Article

References (45)

1. Bauer HC, Brosjo O, Kreicbergs A, Lindholm J. Low risk of recurrence of enchondroma and low-grade chondrosarcoma in extremities. 80 patients followed for 2-25 years. Acta Orthop Scand. 1995;66:283-288.
2. Campanacci M. Bone and Soft Tissue Tumors. 1st ed. New York: Springer; 1990:265-338.
3. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40:818-831.
4. Healey JH, Lane JM. Chondrosarcoma. Clin Orthop Relat Res. 1986;204:119-129.
5. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9-24.
6. Mankin HJ, Cantley KP, Schiller AL, Lippiello L. The biology of human chondrosarcoma. II. Variation in chemical composition among types and subtypes of benign and malignant cartilage tumors. J Bone Joint Surg Am. 1980;622:176-188.
7. Dahlin DC, Henderson ED. Chondrosarcoma, a surgical and pathological problem; review of 212 cases. J Bone Joint Surg Am. 1956;38-A:1025-1038.
8. Dorfman HD, Czerniak B. Bone Tumors. St. Louis: Mosby; 1998:353-440.
9. Lane JM.Malignant bone tumors. In: Alfonson AE, Gardner B, eds. The Practice of Cancer Surgery. New York: Appleton-Century-Crofts; 1982:307-324.
10. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;1087:949-955.
11. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998-15004.
12. Schmidt AM, Mora R, Cao R, et al. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem. 1994;269:9882-9888.
13. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-1321.
14. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand). 1998; 44:1013-1023.
15. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
16. Moroz OV, Antson AA, Dodson EJ, et al. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr. 2002; 58:407-413.
17. Du Yan S, Zhu H, Fu J, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:5296-5301.
18. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382: 685-691.
19. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507-1515.
20. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405:354-360.
21. Hori O, Brett J, Slattery T, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and coexpression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995;270:25752-25761.
22. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-251.
23. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003;254:375-385.
24. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 2002;62:4805-4811.
25. Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol. 2002;196:163-170.
26. Hsieh HL, Schafer BW, Sasaki N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun. 2003;307:375-381.
27. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep. 2003;10:1863-1868.
28. Hermani A, Hess J, De Servi B, et al. Calcium-binding proteins S100A8 and SJ00A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005;11:5146-5152.
29. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097-1109.
30. Cheng C, Tsuneyama K, Kominami R, et al. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol. 2005;18: 1385-1396.
31. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol. 2004;17:1141-1149.
32. Scotlandi K, Serra M, Manara MC, et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer. 1995;75:806-814.
33. Sakurai S, Yamamoto Y, Tamei H, et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract. 2006;73:158-165.
34. Henderson ED, Dahlin DC. Chondrosarcoma of bone - a study of two hundred and eighty-eight cases. J Bone Joint Surg Am. 1963;45:1450-1458.
35. Kreicbergs A, Boquist L, Borssen B, Larsson SE. Prognostic factors in chondrosarcoma: a comparative study of cellular DNA content and clinicopathologic features. Cancer. 1982;50: 577-583.
36. Herget GW, Neuburger M, Adler CP. Prognostic significance of nuclear DNA content in chondrosarcoma. Ann Diagn Pathol. 2000;4:11-16.
37. Lee FY, Mankin HJ, Fondren G, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. 1999;81:326-338.
38. Nawa G, Ueda T, Mori S, et al. Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas. Int J Cancer. 1996;69:86-91.
39. Rizzo M, Ghert MA, Harrelson JM, Scully SP. Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop Relat Res. 2001;391:224-233.
40. Oshiro Y, Chaturvedi V, Hayden D, et al. Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study. Cancer. 1998;83:2324-2334.
41. Martin JA, DeYoung BR, Gitelis S, et al. Telomerase reverse transcriptase subunit expression is associated with chondrosarcoma malignancy. Clin Orthop Relat Res. 2004; 426:117-124.
42. Dijkhuizen T, van den Berg E, Molenaar WM, et al. Cytogenetics as a tool in the histologic subclassification of chondrosarcomas. Cancer Genet Cytogenet. 1994;76:100-105.
43. Gruber HE, Marshall GJ, Kirchen ME, Menendez LR, Schwinn CR Bone remodelling in the presence of chondrosarcoma: histomorphometry. Acta Anat (Basel). 1993;148:1-7.
44. Tsuchiya H, Ueda Y, Morishita H, et al. Borderline chondrosarcoma of long and flat bones. J Cancer Res Clin Oncol. 1993;119:363-368.
45. Springfield DS, Gebhardt MC, McGuire MH. Chondrosarcoma: a review. Instr Course Lect. 1996;45:417-424.